Proton therapy is redefining what radiation can do. Where conventional X-ray radiotherapy scatters energy as it travels through the body, a proton beam releases almost all of its dose precisely at the tumour — then stops. That physical property, known as the Bragg peak, allows oncologists to deliver a lethal dose to a cancer target while the surrounding healthy tissue absorbs a fraction of what it would from standard radiation. The result: a treatment that is more targeted, often better tolerated, and increasingly available to patients worldwide through specialised cancer centres.

What is proton therapy?

Proton therapy — also called proton beam radiotherapy or IMPT (intensity-modulated proton therapy) — is a form of external-beam radiation that uses streams of protons, the positively charged particles found in the nucleus of every atom. Unlike X-rays, which deposit energy continuously as they pass through the body, protons travel to a pre-set depth and then release a concentrated burst of energy at that point before stopping almost completely. This gives clinicians an extraordinary degree of control over where the radiation dose lands.

The technology to harness this effect requires a synchrotron or cyclotron — a large accelerator that energises the protons — and a rotating delivery arm called a gantry, which steers the beam toward the tumour from multiple angles as it rotates around the patient. Proton therapy centres are specialised facilities that exist at leading cancer hospitals and research institutes around the world.

How proton therapy works: the Bragg peak

The defining physics of proton therapy is the Bragg peak: as a proton beam travels through tissue, it deposits relatively little energy along the way, then reaches a maximum at a specific depth — determined by the beam’s initial energy — before falling to near zero. In practice, oncologists spread this peak across the tumour volume (the “spread-out Bragg peak”) to cover the entire target with a high dose.

The clinical significance is twofold. First, the tissue in front of the tumour receives substantially less radiation than with conventional photon therapy. Second, and most importantly, the tissue behind the tumour receives almost none. Research published in Cancer Medicine (PMC, 2021) confirmed that “the low entrance dose and maximum energy deposition in depth… can spare irradiation of proximal healthy tissues and organs at risk when compared to conventional radiotherapy using high-energy photons.” This translates directly into fewer side effects and a lower risk of radiation-related damage to adjacent organs.

Treatment planning begins with detailed CT and often MRI imaging to map the tumour and the organs around it. The patient lies on a table inside the gantry while the beam is delivered; the actual irradiation takes one to two minutes per session. Depending on the cancer type, a full course runs over four to seven weeks of daily outpatient sessions — though hypofractionated (shorter) protocols are increasingly used for selected tumours.

What conditions does proton therapy treat?

Proton therapy is most beneficial when the tumour is adjacent to critical, radiation-sensitive structures. The U.S. National Library of Medicine (MedlinePlus) notes it is used for cancers of the brain, eye, head and neck, lung, spine, prostate, and lymphatic system. Specific indications include:

• Paediatric brain tumours and childhood cancers — protecting the developing nervous system, endocrine glands, and growing bones from the long-term effects of radiation
• Skull-base and spinal tumours — chordomas and chondrosarcomas situated millimetres from the brainstem or spinal cord
• Head and neck cancers — salivary gland tumours, nasopharyngeal carcinoma, and cancers near the eyes or optic nerves
• Ocular cancers — ocular melanoma and retinoblastoma, where sparing the eye itself is critical
• Prostate cancer — with established long-term cancer-control data
• Non-small cell lung cancer (NSCLC) — particularly in patients who cannot tolerate surgery
• Oesophageal, liver, and pancreatic tumours — where dose to surrounding organs is a limiting factor with conventional radiation

Researchers are also investigating proton therapy for breast cancer, glioblastoma, and certain non-cancerous conditions such as macular degeneration.

What the evidence shows

Clinical data on proton therapy outcomes continue to accumulate. Published studies report:

• Stage I non-small cell lung cancer: a PMC study (NCT registry, Radiation Oncology, 2018) reported a 3-year overall survival rate of 87% and a 3-year local control rate of 96% in patients treated with image-guided proton therapy, with low rates of severe toxicity.
• Major salivary gland cancer: a 2021 PMC study found 2-year local control of 96% and 2-year overall survival of 89% with no late grade-3 or higher toxicities reported.
• Prostate cancer: long-term data published in PMC (Cancer, 2017) demonstrated high biochemical cancer-control rates with a favourable side-effect profile comparable to other advanced radiation modalities.
• Paediatric brain tumours: a large single-centre retrospective review (PMC, 2024) reported a 5-year cumulative incidence of brain necrosis of only 2.3% and secondary cancer risk of 2.7% — underscoring the long-term safety advantage when treating children.

It is important to note that outcomes vary significantly by cancer type, stage, and individual patient factors. Published figures represent population averages from clinical studies and do not predict results for any specific case.

The benefits at a glance

• Precision dosing — the Bragg peak confines maximum dose to the tumour, limiting radiation exposure to healthy tissue beyond it
• Fewer side effects — MedlinePlus (NIH) notes that side effects “tend to be milder than with x-ray radiation because proton therapy causes less damage to healthy tissues”
• Organ preservation — critical for cancers near the brain, spinal cord, eyes, or major vessels
• Paediatric advantage — reduced radiation bath lowers the lifetime risk of secondary cancers and developmental complications in children
• Higher doses possible — sparing healthy tissue means oncologists can sometimes deliver a higher, more effective dose to the tumour itself
• Outpatient treatment — no surgery, no hospitalisation; most patients return to normal activities after each session

What to expect

Before treatment starts, the radiation oncology team creates a precise, personalised treatment plan. The patient is fitted with an immobilisation device — a mask for head and neck treatments, a mould for body treatments — to ensure exact reproducibility across every session. Imaging is taken at the planning stage and often again before each session to verify positioning.

During each session, the patient lies on the treatment table inside the gantry room. The actual irradiation lasts one to two minutes. The procedure is painless and there is no radioactivity afterward. Side effects, when they occur, are typically mild — temporary skin redness or fatigue — and are generally less pronounced than those associated with standard photon radiotherapy. Follow-up assessments are usually scheduled every three to four months after the course is complete.

Accessing proton therapy with Medical E-Aid

Proton therapy is available only at a select number of highly specialised centres globally, and navigating access — from obtaining an accurate diagnosis through to choosing the right facility and managing the logistics of travel — can be complex. Medical E-Aid connects patients with internationally accredited centres offering proton beam therapy, coordinates a medical review of your case by specialist oncologists, and supports every step of the treatment journey: obtaining a treatment plan and cost estimate, visa and travel arrangements, interpretation services, and post-treatment follow-up. Our AI-powered pre-screening helps match your specific tumour type and stage to the most appropriate specialists and facilities worldwide.

This article is for general information only and is not medical advice. Treatment suitability depends on each patient’s individual diagnosis, tumour characteristics, and overall health, and must be determined by qualified oncology specialists. Outcome figures are drawn from published peer-reviewed studies and represent population averages; individual results may differ significantly.

Sources: MedlinePlus — Proton Therapy (U.S. National Library of Medicine, reviewed May 2024); “Physical and Biological Characteristics of Particle Therapy for Oncologists,” Cancer Medicine, PMC8291193 (2021); “Clinical outcomes of image-guided proton therapy for histologically confirmed stage I non-small cell lung cancer,” Radiation Oncology, PMC6180633 (2018); “Proton Therapy for Major Salivary Gland Cancer: Clinical Outcomes,” PMC8270094 (2021); “Long-term outcomes in patients treated with proton therapy for localized prostate cancer,” PMC5633560 (2017); “Analysis of brain necrosis and secondary cancers after proton beam therapy for pediatric intracranial tumors,” PMC12463622 (2024).